Overview
NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.
Last reviewed: 22 October 2025
Next review: We will review this decision if the company decides to make a submission.